Each mL contains: Latanoprost 50 μg.
Excipients/Inactive Ingredients: Preservative: Benzalkonium Chloride 0.02 %.
Pharmacology: Latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humor.
Reduction of elevated intraocular pressure in patients with open-angle glaucoma, chronic angle closure glaucoma and ocular hypertension.
The recommended dosage for adults (including the elderly): Recommended therapy is one drop in the affected eye(s) once daily in the evening.
Safety and effectiveness in children has not established. Therefore Latanoprost is not recommended for use in children.
Hypersensitivity to Latanoprost or any other ingredients in this product.
Special warnings and special precautions for use: Benzalkonium Chloride, which is commonly used as preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since this drug contains Benzalkonium Chloride, close monitoring is required in frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.
Contact lenses: Patients should be advised not to wear contact lenses if their eye is red. This drug should not be used to treat contact lenses-related irritation. The preservative in this drug, Benzalkonium Chloride, may be absorbed by contact lenses. Patients who wear contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instilling this drug before they insert their contact lenses.
Latanoprost may gradually change the eye colour by increasing the amount of brown pigment in the iris.
There is no experience of Latanoprost in inflammatory, neovascular, angle closure or congenital glaucoma and only limited experience in open angle glaucoma of pseudophakic patients and in pigmentary glaucoma. Latanoprost has no or little effect on the pupil but there is no experience in accurate attacks of closed angle glaucoma. Therefore it is recommended that Latanoprost should be used with caution in these conditions until more experience is obtained.
Macular oedema, including cystoid macular oedema, has been reported during treatment with Latanoprost. These reports have mainly occurred in aphakic patients, in pseudophakic patients with torn posterior lens capsule, or in patients with known risk factors for macular edema. Latanoprost should be used with caution in these patients.
Latanoprost should be used with caution during pregnancy and nursing women.
Latanoprost should be used with caution during pregnancy and nursing women.
Latanoprost has caused increased pigmentation of the iris.
Latanoprost may cause darkening, thickening and lengthening of eye lashes. Darkening of the palpebra skin of the eye lids has very rarely been notes.
Latanoprost may slight foreign body sensation.
Macular oedema has been reported rarely during Latanoprost treatment.
Rare cases of asthma, asthma aggravation, acute asthma attack and dyspnoea have been reported.
Skin rash of unknown etiology has been rarely reported during Latanoprost treatment.
The intraocular pressure reducing effect of Latanoprost has been shown to be additive to that of beta-adrenergic antagonists (timolol), adrenergic agonists (dipivalyl epinephrine), carbonic anhydrase inhibitors (acetazolamide), and at least partly to cholinergic agonist (pilocarpine) in short term clinical trials.
Store between 2°C and 8°C, away from light.
After opening, store below 25°C and use within 4 weeks.
S01EE01 - latanoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Lanosan Eye Drops 50 mcg/mL
(dropper tip bottle) 2.5 mL x 1's (Rp118,800/boks)
Sign Out
